GlassScriptPhysician profile
Brian D Mcdowell
NPI 1962815787
$6,880.84
in general payments reported to CMS, 2019-2025
30 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,097 · 2022: $1,522 · 2023: $1,174 · 2024: $970 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,246 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,245.96 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $979.80 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $888.70 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $801.10 | 2021-2025 | Lifevest |
| Amgen INC. | $679.67 | 2021-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $426.76 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $340.96 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $340.23 | 2021-2024 | Verquvo |
| Novo Nordisk INC | $337.45 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $247.47 | 2021-2025 | Cardiomems |
| Endotronix, INC. | $245.30 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Pfizer INC. | $234.38 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $228.45 | 2021-2024 | Brilinta, Andexxa |
| Amarin Pharma, INC. | $174.86 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $173.34 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $168.45 | 2023-2025 | Camzyos, Eliquis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $98.30 | 2022-2025 | Atriclip Laa Exclusion System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.66 | 2021-2024 | Jardiance |
| Edwards Lifesciences Corporation | $69.82 | 2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $65.96 | 2022-2024 | Watchman Flx, Bodyguardian |
| Chiesi USA, INC. | $50.24 | 2021-2022 | |
| Astellas Pharma US INC | $47.93 | 2021-2022 | |
| Biotronik INC. | $41.22 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $37.93 | 2021 | |
| Abiomed | $33.17 | 2025 | |
| Vital Connect, INC | $20.28 | 2025 | Vitalpatch Rtm |
| Daiichi Sankyo INC. | $16.61 | 2023 | Injectafer |
| Janssen Biotech, INC. | $14.59 | 2023 | Darzalex, Imbruvica |
| Octapharma USA, INC. | $13.47 | 2025 | Balfaxar |
| Amryt Pharma Holdings LTD | $12.80 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.